For your doctor · treatment-resistant depression

Discussing it with your doctor, without imposing anything.

Many physicians have never had the opportunity to use classic MAOIs — they now account for less than 0.1% of prescriptions. Here is a short, respectful letter to print and bring to an appointment, simply to open the discussion — together with reliable medical sources that a practitioner can verify.

Letter adapted to your country
parnate.ch Date:

For the attention of my doctor

Dear Doctor,

I would like to put forward a possible subject for discussion regarding my treatment. While trying to understand depression that resists usual treatments, I learned about an older class of antidepressants: the so-called “classic” MAOIs — tranylcypromine (Parnate), phenelzine (Nardil) and isocarboxazid (Marplan).

My understanding is that they are among the most effective options for treatment-resistant forms, but are now prescribed very rarely — not because they lack efficacy, but because they require specific know-how: a low-tyramine diet and certain drug combinations that must be avoided. I understand that these are not trivial treatments.

I am certainly not trying to tell you what course to follow: I would simply like to know whether this option could, at some point, make sense in my situation — and, if so, to discuss it with you.

To make this easier, I have listed below a few recent, reliable medical references, including an open-access prescribing guide endorsed by more than 70 international experts.

Thank you for considering this. I remain open to your advice.

Yours sincerely,
your name

A few references, Doctor

• Van den Eynde V, Gillman PK, et al. “The prescriber's guide to classic MAO inhibitors… for treatment-resistant depression.” CNS Spectrums 2023;28(4):427–440. Open access: doi.org/10.1017/S1092852922000906

• Ulrich S, Ricken R, Adli M. « Tranylcypromine in mind (Part I & II). » European Neuropsychopharmacology 2017;27(8):697–731.

• General information: parnate.ch

Tip: click “your name” in the letter to replace it before printing. Today’s date is inserted automatically.

For your doctor — the sources

What carries weight with a practitioner is not a website but a verifiable primary source. Here are the references underlying this page. The originals are in English (one is in German); the summaries below are ours.

The prescribing guide (the most useful) Open access · CC-BY
Van den Eynde V, Gillman P. K., et al. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectrums (Cambridge University Press), 2023;28(4):427–440.
A practical guide endorsed by more than 70 international experts for prescribers: indications (treatment-resistant depression), washout intervals, interactions to avoid, management of adverse effects and combination strategies. Its recurring message is that MAOIs should be considered far more often than they are. Open access (CC-BY licence) — I have written an English summary on this site. Read the original (free PDF)
Tranylcypromine in mind — Part I (pharmacology) English
Ulrich S, Ricken R, Adli M. European Neuropsychopharmacology, 2017;27(8):697–713.
The first in-depth review of tranylcypromine pharmacology in more than 50 years: mechanism of action, doses, pharmacokinetics and interactions. PubMed record
Tranylcypromine in mind — Part II (efficacy) English
Ricken R, Ulrich S, Schlattmann P, Adli M. European Neuropsychopharmacology, 2017;27(8):714–731.
A meta-analysis of controlled studies confirming the efficacy of tranylcypromine in depression, including treatment-resistant forms. PubMed record
German review (tranylcypromine & treatment-resistant depression) German
Originalarbeit, Psychopharmakotherapie (PPT), 2019;26(1). © Wissenschaftliche Verlagsgesellschaft Stuttgart.
A German-language summary of tranylcypromine in treatment-resistant depression (about 58% responders in controlled studies) and options for non-responders. This is a protected document that cannot be redistributed; it can be consulted from the publisher (ppt-online.de).

This website provides general information and cannot replace advice from a physician or pharmacist. Do not make any treatment decision without a healthcare professional. MAOIs involve real precautions — dietary and, above all, drug-interaction precautions — which are detailed on the relevant pages.